- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06886815
Popliteal -Nervenblock für Achilles Sehnenreparaturchirurgie
Der Effekt des Popliteal -Nervenblocks auf die Erholung nach Achilles -Sehnenreparaturoperation: Eine randomisierte kontrollierte Studie
Achilles tendon rupture is common, yet the value of popliteal nerve block for postoperative pain control during surgical repair remains uncertain. Despite widespread use, evidence supporting its analgesic effectiveness is limited, and both popliteal nerve block and Achilles tendon repair carry risks of nerve injury. This randomized, placebo-controlled trial will evaluate whether adding a popliteal nerve block to standard systemic analgesia improves postoperative pain and reduces opioid use in patients undergoing acute Achilles tendon rupture repair. Secondary outcomes will examine the incidence and impact of nerve complications on recovery, including return to physical activity and functional performance.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This will be a prospective, double-blinded, randomized controlled superiority trial conducted at Women's College Hospital (WCH). The study aims to enroll 80 patients (40 per group) undergoing ambulatory surgical repair of acute Achilles tendon ruptures.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Didem Bozak
- Telefonnummer: 416-323-6008
- E-Mail: didem.bozak@wchospital.ca
Studienorte
-
-
Ontario
-
Toronto, Ontario, Kanada, M5S 1B2
- Rekrutierung
- Women's College Hospital
-
Hauptermittler:
- Richard Brull, MD,FRCPC
-
Kontakt:
- Didem Bozak
- Telefonnummer: 416-323-6008
- E-Mail: didem.bozak@wchospital.ca
-
Unterermittler:
- Connor TA Brenna, MD
-
Unterermittler:
- Seung C Kim, MD,FFPMRCA
-
Unterermittler:
- Faraj W Abdallah, MD,FRCPC
-
Unterermittler:
- Sam Park, MD,MASc
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age 18 - 65
- ASA classification: I - III
- BMI < 35 kg/m2
- Undergoing acute Achilles tendon rupture repair surgery as a day surgery procedure
Exclusion Criteria:
- Pre-existing neurological deficits or peripheral neuropathy in the distribution of the tibial or common peroneal nerves
- Local infection
- Contraindication to regional anesthesia (e.g., bleeding diathesis, coagulopathy)
- History of use of over 30 mg oxycodone or equivalent per day
- Contraindication to any component of a standard multi-modal analgesia
- Allergy to local anesthetics
- History of significant psychiatric conditions that may affect patient assessment
- Pregnancy
- Inability to provide informed consent
- Patient refusal of popliteal nerve blockade
- Prior Achilles tendon surgeries on the operative leg
- Unable to speak or read English
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Popliteal nerve (PN) block group
30 mL of 0.5% ropivacaine with 2.5 µg/ml of epinephrine |
Under ultrasound guidance, a 22G, 80-mm echogenic needle (SonoTAP II, Pajunk Medical Systems, USA) will be inserted using an in-plane lateral-to-medial approach. 30 mL of 0.5% ropivacaine with 2.5 µg/ml of epinephrine will be deposited between tibial and common peroneal nerves within the paraneural sheath. Adequate spread of local anesthetics will be confirmed by visualization of paraneural spread.
Andere Namen:
|
|
Schein-Komparator: Placebo Nerve Block
1 mL of saline |
Patients in the Control group will receive sham blocks using a 25G needle to inject 1 mL of saline subcutaneously in the same location (popliteus of the surgical knee). Sterilization and ultrasound scanning will match actual PN block. Such a non-invasive placebo allows maintaining patient blinding, while reducing the risks associated with high-volume placebo nerve block injections. The ultrasound screen will be blinded from the patient's vision for all patients in the trial to prevent unblinding by patients with knowledge of the technique. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Cumulative Opioid Consumption
Zeitfenster: The first 24 hours after surgery
|
Total opioid dose administered to each patient, converted to oral morphine equivalents. |
The first 24 hours after surgery
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Area Under the Curve for Postoperative Pain
Zeitfenster: The first 24 hours after surgery
|
Area under the curve calculated from discrete Numeric Rating Scale evaluations of postoperative pain (0 - 10), where 0 corresponds to no pain, and 10 corresponds to the worst pain imaginable. Pain will be measured on this scale at 0, 6, 12, 18, and 24 hours after surgery. |
The first 24 hours after surgery
|
|
Quality of Recovery
Zeitfenster: At baseline, 6, 24, 48 hours, 7 days and 1-year post-surgery
|
Quality of recovery evaluated using the QoR-15 scale (0 - 150), where 0 represents extremely poor recovery and 150 represents excellent recovery. |
At baseline, 6, 24, 48 hours, 7 days and 1-year post-surgery
|
|
Postoperative Pain Score
Zeitfenster: At baseline, 0, 6, 12, 18, 24, 36, 48 hours, 7 days and 1-year post-surgery.
|
Measured using the Numeric Rating (NRS) Scale (0 - 10) where 0 corresponds to no pain, and 10 corresponds to the worst pain imaginable. |
At baseline, 0, 6, 12, 18, 24, 36, 48 hours, 7 days and 1-year post-surgery.
|
|
Intraoperative Opioid Consumption
Zeitfenster: The first 24 hours after surgery
|
Measurement of opioids administered during surgery, converted into oral morphine equivalents. |
The first 24 hours after surgery
|
|
Time to Analgesic Request
Zeitfenster: The first 24 hours after surgery
|
Length of time until the patient's first request for analgesics following surgery. |
The first 24 hours after surgery
|
|
Time to Discharge
Zeitfenster: The first 24 hours after surgery
|
The length of time each patient stays in Phase I (Postanesthesia Care Unit) and Phase II (Surgical Day Care) after surgery. |
The first 24 hours after surgery
|
|
Adverse Events Attributable to Popliteal Block
Zeitfenster: At 0, 6, 12, 18, 24, 36, 48 hours, 7 days and 1-year post-surgery
|
The incidence of adverse events possibly attributable to popliteal nerve block, including peripheral nerve injury, hematoma, and infection. |
At 0, 6, 12, 18, 24, 36, 48 hours, 7 days and 1-year post-surgery
|
|
Adverse Events Attributable to Opioids
Zeitfenster: Evaluated at 24 and 48 hours after surgery.
|
The incidence of opioid-related side effects, including sedation, pruritis, nausea/vomiting, and respiratory depression. |
Evaluated at 24 and 48 hours after surgery.
|
|
Pain, fatigue, and physical function
Zeitfenster: Prior to surgery and 1-year post-surgery
|
Measured using the Achilles tendon Total Rupture Score (ATRS) |
Prior to surgery and 1-year post-surgery
|
|
Neuropathic pain
Zeitfenster: At 1 week and 1-year post-surgery
|
Measured using the English version of the Douleur Neuropathique 4 (DN4) Questionnaire |
At 1 week and 1-year post-surgery
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Richard Brull, MD, FRCPC, University Health Network, Toronto
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Brenna CTA, Khan S, Abdallah FW, Brull R. Achilles Hero or Heel? A Systematic Review of Popliteal Nerve Block for Achilles Repair. Foot & Ankle Surgery: Techniques, Reports & Cases. 2025:100474.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- 2025-0039-B
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .